Adaptive Biotechnologies Corp Cash Flow-to-Debt Ratio
Adaptive Biotechnologies Corp cash flow-to-debt ratio. Adaptive Biotechnologies Corp (ADPT) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of $-7.13 Million could theoretically repay 0% of its total liabilities ($286.36 Million) in one year. Check ADPT cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Adaptive Biotechnologies Corp (2017–2024)
Cash flow-to-debt ratio of Adaptive Biotechnologies Corp from 2017 to 2024. Historical debt coverage capacity for Adaptive Biotechnologies Corp across 8 annual periods. Check cash flow reinvestment rate of Adaptive Biotechnologies Corp to assess the company's total reinvestment commitment from operating cash flow.
Adaptive Biotechnologies Corp Cash Flow-to-Debt Ratio by Year (2017–2024)
Adaptive Biotechnologies Corp cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Adaptive Biotechnologies Corp. For the full cash flow conversion analysis, see Adaptive Biotechnologies Corp operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.28x | $-95.21 Million | $336.89 Million | ▲ +36.2% |
| 2023 | -0.44x | $-156.32 Million | $352.86 Million | ▲ +5.5% |
| 2022 | -0.47x | $-183.94 Million | $392.52 Million | ▲ +22.4% |
| 2021 | -0.60x | $-192.73 Million | $319.24 Million | ▼ -50.5% |
| 2020 | -0.40x | $-149.68 Million | $373.15 Million | ▼ -166.6% |
| 2019 | 0.60x | $205.40 Million | $341.26 Million | ▲ +1202.3% |
| 2018 | -0.05x | $-32.26 Million | $590.80 Million | ▲ +8.0% |
| 2017 | -0.06x | $-34.86 Million | $587.11 Million | — |